Transaction DateRecipientSharesTypePriceValue
29th September 2020David J. Marguglio20,000Open or private sale$0.80$16,000.00
29th September 2020Robert O Hopkins20,000Open or private sale$0.80$16,000.00
18th August 2020Karen K. Daniels5,480Open or private sale$0.87$4,790.07
18th August 2020Ronald B. Moss8,749Open or private sale$0.87$7,647.50
18th August 2020Dennis J Phd Carlo10,929Open or private sale$0.87$9,553.04
18th August 2020David J. Marguglio8,749Open or private sale$0.87$7,647.50
18th August 2020Robert O Hopkins7,418Open or private sale$0.87$6,484.07
19th May 2020Karen K. Daniels4,855Open or private sale$0.56$2,719.29
18th May 2020Robert O Hopkins6,532Open or private sale$0.56$3,658.57
18th May 2020David J. Marguglio7,734Open or private sale$0.56$4,331.81
Adamis Pharmaceuticals
Adamis Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of -2/10.

Adamis Pharmaceuticals Corp. engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. The company offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED) markets.

Ticker: ADMP
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 887247
Employees: 171
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $8 M (-10%)
Inventory, Net: $2 M (0%)
Assets, Current: $12 M (-13%)
Property, Plant and Equipment, Net: $11 M (0%)
Other Assets, Noncurrent: $55 Th (-96%)
Assets: $40 M (-17%)
Accounts Payable, Current: $4 M (0%)
Accrued Liabilities, Current: $2 M (-6%)
Liabilities, Current: $12 M (31%)
Liabilities: $17 M (40%)
Common Stock, Value, Issued: $7 Th (19%)
Common Stock, Shares, Issued: $74 M (19%)
Additional Paid in Capital, Common Stock: $227 M (3%)
Retained Earnings (Accumulated Deficit): $204 M (11%)
Treasury Stock, Value: $52 Th (0%)
Treasury Stock, Shares: $5 M (0%)
Liabilities and Equity: $40 M (-17%)
Revenue: $4 M (0%)
Cost of Revenue: $5 M (0%)
Gross Margin: $757 Th (0%)
Research and Development: $3 M (0%)
Operating Income/Loss: $11 M (0%)
Other Income, net: $16 Th (-48%)
Income before taxes: $11 M (-47%)